Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

NCT00679172 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

Typhoid

Interventions

BIOLOGICAL: Dose of 5.0 x 10^9 CFU (Cohort 1)
BIOLOGICAL: Dose of 7.5 x 10^9 CFU (Cohort 2)
BIOLOGICAL: Dose of 1.1 x 10^10 CFU (Cohort 3)
BIOLOGICAL: Dose of of 1.7 x 10^10 CFU (Cohort 4)
OTHER: Placebo (Cohorts 1-4 pooled)

Sponsor

Emergent BioSolutions